[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607936":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":20,"locations":25,"responsibleParty":45,"collaborators":20,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":28,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Children's Mercy Hospital Kansas City","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Measles, Mumps, Rubella Vaccination","EXPERIMENTAL","Patients receiving MMR vaccination due to no historical vaccine OR a seronegativity for measles",[13],"Drug: Commercial measles, mumps, and rubella (MMR) vaccine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Commercial measles, mumps, and rubella (MMR) vaccine","Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Victoria Blazek, PharmD, BCPPS","PRINCIPAL_INVESTIGATOR",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Children's Mercy Hospital","RECRUITING","Kansas City","Missouri","64108","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-94.57857,39.09973,{"lat":38,"lon":37},[41],{"name":23,"role":42,"phone":43,"phoneExt":20,"email":44},"CONTACT","816-302-3724","vmblazek@cmh.edu",{"type":24,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Victoria Blazek","Clinical Pharmacy Specialist","100607936",false,"NCT07195032","Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","Inclusion Criteria:\n\n* Received a heart transplant\n* At least 1 year after transplant\n* At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)\n* At least 1 year from anti-thymocyte globulin\n* At least 6 months after pulse dose steroid treatment or basiliximab treatment\n* No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion\n* Clinically well\n\nExclusion Criteria:\n\n* History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.\n* History of anaphylactic reaction to MMR vaccination","ALL","1 Year","17 Years",{"count":57,"type":58},60,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission\u002Fassent will receive the commercial MMR vaccine according to product indication and labeling.",[64],"Heart Transplant Infection Prevention",[66,67,68,69,70],"Measles","Mumps","Rubella","Live vaccine","Heart transplant","2025-09-19",{"date":73,"type":74},"2025-09-26","ACTUAL",{"date":76,"type":74},"2025-09-11",{"date":78,"type":58},"2027-09-11",{"name":5,"class":6},1]